A 60-year-old female presents to her gynecologist with bloating, abdominal discomfort, and fatigue. She has a history of hypertension and takes hydrochlorothiazide. Physical exam reveals ascites and right adnexal tenderness. Initial imaging reveals a mass in the right ovary and eventual biopsy of the mass reveals ovarian serous cystadenocarcinoma. She is started on a chemotherapeutic agent with plans for surgical resection. Soon after starting the medication, she develops dysuria and hematuria. Laboratory analysis of her urine is notable for the presence of a cytotoxic metabolite. Which of the following mechanisms of action is consistent with the medication in question?
Q162
A 71-year-old man with asthma and dementia presents to the emergency department in acute respiratory distress. He is with his home care nurse who explains that he has been hiding his bronchodilators for the past 3 weeks, and she has had to dutifully look for them and help him administer them. Over the past 2 days, however, she has been completely unsuccessful in finding his medication and was in the process of contacting his primary care physician for a refill of his prescription when he suddenly had a ‘coughing fit’ and began wheezing uncontrollably. The patient is obviously uncomfortable and is using accessory muscles of respiration to catch his breath. He is struggling to speak and is immediately given multiple doses of nebulized albuterol and intravenous methylprednisolone; however, his condition does not improve. The arterial blood gas test result shows pH 7.20. He is subsequently intubated and sent to the intensive care unit (ICU). In patients who are intubated for mechanical ventilation, there is an increased risk for ventilator-associated pneumonia. Which of the following should be prophylactically given to this patient to lower his risk for pneumonia?
Q163
A 52-year-old man presents to his primary care physician because he has been experiencing shortness of breath and cough. He began feeling short of breath when playing recreational soccer with his friends. Over time these episodes have become more severe. They now impair his ability to work as a construction worker. In addition, he has developed a chronic dry cough that has been increasing in intensity. Radiography reveals subpleural cystic enlargement, and biopsy reveals fibroblast proliferation in the affected tissues. Which of the following describes the mechanism of action for a drug that can cause a similar pattern of pulmonary function testing as would be seen in this disease?
Q164
A 64-year-old woman comes to the physician because of a 7-month history of abdominal discomfort, fatigue, and a 6.8-kg (15-lb) weight loss. Physical examination shows generalized pallor and splenomegaly. Laboratory studies show anemia with pronounced leukocytosis and thrombocytosis. Cytogenetic analysis shows a BCR-ABL fusion gene. A drug with which of the following mechanisms of action is most appropriate for this patient?
Q165
An 18-month-old boy is brought to the physician because of walking difficulties. His mother says that he cannot walk unless he is supported. She has also noted orange, sandy residues in his diapers. Over the past year, she has frequently caught him pulling his toenails and chewing the tips of his fingers. Examination shows scarring of his fingertips. Muscle tone is decreased in the upper and lower extremities. He cannot pick up and hold small objects between the tips of the index finger and the thumb. The most appropriate pharmacotherapy for this patient's condition inhibits which of the following conversions?
Q166
A 60-year-old man is rushed to the emergency room after he was found unconscious in bed that afternoon. The patient’s wife says he has been confused and irritable for the past several days. She says he has a history of chronic daily alcohol abuse and has been hospitalized multiple times with similar symptoms His temperature is 37°C (98.6°F), the blood pressure is 110/80 mm Hg, the pulse is 90/min, and the respiratory rate is 14/min. On physical examination, the patient is minimally responsive to painful stimuli. His abdomen is distended with positive shifting dullness. Laboratory results are as follows:
Complete blood count
Hematocrit 35%
Platelets 100,000/mm3
White blood cells 5000/mm3
Liver function studies
Serum Albumin 2 g/dL
Alkaline phosphatase (ALP) 200 IU/L
Aspartate aminotransferase (AST) 106 IU/L
Alanine aminotransferase (ALT) 56 IU/L
The patient is admitted to the hospital and started on the appropriate treatment to improve his mental status. Which of the following best describes the mechanism of action of the drug that is most likely used to treat this patient’s symptoms?
Q167
A 25-year-old man presents with abdominal pain and bloody diarrhea. His symptoms have been recurrent for the past few months, and, currently, he says he is having on average four bowel movements daily, often bloody. He describes the pain as cramping and localized to the left side of his abdomen. He also says that he has lost around 4.5 kg (10 lb) over the past 3 months. There is no other significant past medical history and the patient is not on current medications. His temperature is 37.7° C (100.0° F), pulse rate is 100/min, respiratory rate is 18/min, and blood pressure is 123/85 mm Hg. On physical examination, there is mild tenderness to palpation in the lower left quadrant of the abdomen with no rebound or guarding. Laboratory studies show anemia and thrombocytosis. Colonoscopy is performed, which confirms the diagnosis of ulcerative colitis (UC). What is the mechanism of action of the recommended first-line medication for the treatment of this patient’s condition?
Q168
A 46-year-old male presents to his dermatologist for routine follow-up of his psoriasis. He was last seen in the office six months prior, at which time he started undergoing ultraviolet light therapy. He reports that he initially noticed an improvement in his symptoms but the effects were transient. He has also started noticing pain and stiffness in his fingers. His past medical history is notable for obesity and diabetes mellitus. He takes metformin. His temperature is 99°F (37.2°C), blood pressure is 130/80 mmHg, pulse is 80/min, and respirations are 16/min. Multiple plaques with scaling are noted on the extensor surfaces of the upper and lower extremities. The patient’s physician suggests stopping the ultraviolet light therapy and starting an injectable medication that acts as a decoy receptor for a pro-inflammatory cytokine. Which of the following is an adverse effect associated with the use of this medication?
Q169
An 8-year-old boy is brought to the emergency department by his parents because of sudden onset of abdominal pain beginning an hour ago. The parents report that their son has also had an episode of dark urine earlier that morning. Three days ago, he was diagnosed with a urinary tract infection and was treated with trimethoprim-sulfamethoxazole. He emigrated from Liberia to the US with his family 3 years ago. There is no personal history of serious illness. His immunizations are up-to-date. Vital signs are within normal limits. Examination shows diffuse abdominal tenderness and scleral icterus. The spleen is palpated 1–2 cm below the left costal margin. Laboratory studies show:
Hemoglobin 10 g/dL
Mean corpuscular volume 90 μm3
Reticulocyte count 3%
Serum
Bilirubin
Total 3 mg/dL
Direct 0.5 mg/dL
Haptoglobin 20 mg/dL (N=41–165 mg/dL)
Lactate dehydrogenase 160 U/L
Urine
Blood 3+
Protein 1+
RBC 2–3/hpf
WBC 2–3/hpf
Which of the following is the most likely underlying cause of this patient's symptoms?
Q170
A 45-year-old male presents to his primary care doctor complaining of abdominal pain. He reports a three-month history of intermittent burning pain localized to the epigastrium that worsens 2-3 hours after a meal. He attributes this pain to increased stress at his job. He is otherwise healthy and takes no medications. He does not smoke or drink alcohol. His temperature is 98.8°F (37.1°C), blood pressure is 130/85 mmHg, pulse is 90/min, and respirations are 18/min. Physical examination reveals mild epigastric tenderness to palpation. A urease breath test is positive. Which of the following treatments is most appropriate first-line therapy for this patient?
Antimicrobials US Medical PG Practice Questions and MCQs
Question 161: A 60-year-old female presents to her gynecologist with bloating, abdominal discomfort, and fatigue. She has a history of hypertension and takes hydrochlorothiazide. Physical exam reveals ascites and right adnexal tenderness. Initial imaging reveals a mass in the right ovary and eventual biopsy of the mass reveals ovarian serous cystadenocarcinoma. She is started on a chemotherapeutic agent with plans for surgical resection. Soon after starting the medication, she develops dysuria and hematuria. Laboratory analysis of her urine is notable for the presence of a cytotoxic metabolite. Which of the following mechanisms of action is consistent with the medication in question?
A. Folate analog
B. Microtubule inhibitor
C. DNA alkylating agent (Correct Answer)
D. Platinum-based DNA cross-linking agent
E. BRAF inhibitor
Explanation: ***DNA alkylating agent***
- Cyclophosphamide is a **DNA alkylating agent** commonly used in the treatment of ovarian cancer. It is metabolized to **acrolein**, a cytotoxic metabolite that causes **hemorrhagic cystitis**, presenting as dysuria and hematuria.
- DNA alkylating agents exert their cytotoxic effects by forming **covalent bonds** with DNA, leading to DNA damage, cross-linking, and subsequent inhibition of DNA replication and transcription, ultimately inducing **apoptosis** in rapidly dividing cancer cells.
*Folate analog*
- Folate analogs like **methotrexate** inhibit **dihydrofolate reductase**, interfering with DNA synthesis by depleting tetrahydrofolate, a crucial cofactor for nucleotide synthesis.
- While they are chemotherapeutic agents, they do not typically cause hemorrhagic cystitis; their common side effects include **myelosuppression**, mucositis, and hepatotoxicity.
*Microtubule inhibitor*
- Microtubule inhibitors such as **paclitaxel** and **vincristine** interfere with microtubule formation or breakdown, disrupting cell division (mitosis).
- Common side effects include **neuropathy** and myelosuppression, but not hemorrhagic cystitis.
*Platinum-based DNA cross-linking agent*
- Platinum-based drugs like **cisplatin** and **carboplatin** are often used for ovarian cancer and cause nephrotoxicity, neurotoxicity, and ototoxicity.
- They form **DNA adducts and interstrand cross-links**, inhibiting DNA replication and transcription, but do not directly cause acrolein-induced hemorrhagic cystitis.
*BRAF inhibitor*
- BRAF inhibitors (e.g., **vemurafenib**) are **targeted therapies** used in cancers with specific mutations, such as BRAF-mutated melanoma.
- They inhibit the BRAF kinase in the MAPK signaling pathway, and while effective in specific contexts, they are not typically associated with hemorrhagic cystitis.
Question 162: A 71-year-old man with asthma and dementia presents to the emergency department in acute respiratory distress. He is with his home care nurse who explains that he has been hiding his bronchodilators for the past 3 weeks, and she has had to dutifully look for them and help him administer them. Over the past 2 days, however, she has been completely unsuccessful in finding his medication and was in the process of contacting his primary care physician for a refill of his prescription when he suddenly had a ‘coughing fit’ and began wheezing uncontrollably. The patient is obviously uncomfortable and is using accessory muscles of respiration to catch his breath. He is struggling to speak and is immediately given multiple doses of nebulized albuterol and intravenous methylprednisolone; however, his condition does not improve. The arterial blood gas test result shows pH 7.20. He is subsequently intubated and sent to the intensive care unit (ICU). In patients who are intubated for mechanical ventilation, there is an increased risk for ventilator-associated pneumonia. Which of the following should be prophylactically given to this patient to lower his risk for pneumonia?
A. Sucralfate (Correct Answer)
B. Clarithromycin
C. Omeprazole
D. Ceftazidime
E. Famotidine
Explanation: ***Correct: Sucralfate***
- **Sucralfate is the preferred agent for stress ulcer prophylaxis** when prevention of ventilator-associated pneumonia (VAP) is a priority in mechanically ventilated patients.
- Unlike acid-suppressing agents, sucralfate **does not alter gastric pH**, which means it prevents bacterial overgrowth in the stomach that can be aspirated into the lungs.
- Multiple meta-analyses have shown that sucralfate is associated with a **lower risk of VAP** compared to proton pump inhibitors (PPIs) and H2 receptor blockers.
- It forms a protective barrier over gastric and duodenal ulcers without raising gastric pH, thereby maintaining the stomach's natural antimicrobial defense.
*Incorrect: Omeprazole*
- Omeprazole is a **proton pump inhibitor (PPI)** that significantly reduces gastric acid production and raises gastric pH.
- While effective for stress ulcer prophylaxis, **PPIs are associated with an increased risk of VAP** (approximately 20-30% increased risk).
- The elevated gastric pH promotes bacterial colonization and overgrowth, which can be aspirated into the respiratory tract.
- Current guidelines recommend **avoiding routine PPI use** in mechanically ventilated patients when VAP prevention is a concern.
*Incorrect: Famotidine*
- Famotidine is an **H2 receptor blocker** that reduces gastric acid secretion.
- Like PPIs, **H2 blockers increase the risk of VAP** by raising gastric pH and allowing bacterial overgrowth.
- While famotidine can be used for stress ulcer prophylaxis, it is **not the preferred choice** when VAP prevention is the primary concern.
- Studies show similar VAP risk increases with H2 blockers as with PPIs.
*Incorrect: Clarithromycin*
- Clarithromycin is a macrolide antibiotic with no role in **prophylaxis against VAP**.
- Routine prophylactic antibiotic use in intubated patients is **not recommended** due to concerns about antimicrobial resistance.
- Antibiotics should be reserved for documented infections, not routine prevention in all mechanically ventilated patients.
*Incorrect: Ceftazidime*
- Ceftazidime is a third-generation cephalosporin antibiotic with activity against **Pseudomonas aeruginosa**.
- It is used for **treatment** of established infections, not for routine prophylaxis against VAP.
- Prophylactic antibiotic use promotes **antibiotic resistance** and is not standard practice for VAP prevention in all intubated patients.
Question 163: A 52-year-old man presents to his primary care physician because he has been experiencing shortness of breath and cough. He began feeling short of breath when playing recreational soccer with his friends. Over time these episodes have become more severe. They now impair his ability to work as a construction worker. In addition, he has developed a chronic dry cough that has been increasing in intensity. Radiography reveals subpleural cystic enlargement, and biopsy reveals fibroblast proliferation in the affected tissues. Which of the following describes the mechanism of action for a drug that can cause a similar pattern of pulmonary function testing as would be seen in this disease?
A. Pyrimidine analogue
B. Microtubule inhibitor
C. Purine analogue
D. Dihydrofolate reductase inhibitor (Correct Answer)
E. Xanthine oxidase inhibitor
Explanation: ***Dihydrofolate reductase inhibitor***
- The patient's symptoms (shortness of breath, dry cough, subpleural cystic enlargement, fibroblast proliferation) are consistent with **pulmonary fibrosis**, which presents as a **restrictive lung disease**.
- **Methotrexate**, a **dihydrofolate reductase inhibitor**, is a known cause of drug-induced pulmonary fibrosis, leading to a restrictive pattern on pulmonary function tests.
*Pyrimidine analogue*
- **Pyrimidine analogues** like **gemcitabine** or **5-fluorouracil** are primarily chemotherapy agents and are not strongly associated with pulmonary fibrosis.
- Their mechanisms typically involve interrupting DNA or RNA synthesis, and while they can have pulmonary side effects, fibrosis is not their characteristic pattern.
*Microtubule inhibitor*
- **Microtubule inhibitors** such as **paclitaxel** or **vincristine** are antineoplastic drugs commonly used in cancer treatment.
- While they can cause various side effects, including neurotoxicity and myelosuppression, **pulmonary fibrosis** is not a common or characteristic adverse effect.
*Purine analogue*
- **Purine analogues** like **azathioprine** or **cladribine** are immunosuppressants and chemotherapeutic agents.
- Although these drugs can have pulmonary toxicity, they are less commonly associated with significant **pulmonary fibrosis** compared to methotrexate.
*Xanthine oxidase inhibitor*
- **Xanthine oxidase inhibitors**, such as **allopurinol** and **febuxostat**, are primarily used to treat **gout** by reducing uric acid production.
- Pulmonary side effects, particularly **pulmonary fibrosis**, are exceedingly rare with this class of drugs.
Question 164: A 64-year-old woman comes to the physician because of a 7-month history of abdominal discomfort, fatigue, and a 6.8-kg (15-lb) weight loss. Physical examination shows generalized pallor and splenomegaly. Laboratory studies show anemia with pronounced leukocytosis and thrombocytosis. Cytogenetic analysis shows a BCR-ABL fusion gene. A drug with which of the following mechanisms of action is most appropriate for this patient?
A. Ribonucleotide reductase inhibitor
B. Monoclonal anti-HER-2 antibody
C. Topoisomerase II inhibitor
D. Monoclonal anti-CD20 antibody
E. Tyrosine kinase inhibitor (Correct Answer)
Explanation: ***Tyrosine kinase inhibitor***
- The patient's symptoms (abdominal discomfort, fatigue, weight loss, pallor, splenomegaly), laboratory findings (**anemia with pronounced leukocytosis and thrombocytosis**), and the presence of a **BCR-ABL fusion gene** are highly characteristic of **Chronic Myeloid Leukemia (CML)**.
- The **BCR-ABL fusion gene** encodes a constitutively active **tyrosine kinase**, which is the hallmark of CML and the primary therapeutic target for **tyrosine kinase inhibitors (TKIs)** like imatinib.
*Ribonucleotide reductase inhibitor*
- **Ribonucleotide reductase inhibitors** (e.g., hydroxyurea) block DNA synthesis and are used in myeloproliferative disorders to reduce cell counts, but they are not specific to the **BCR-ABL fusion gene** and are not the most appropriate first-line targeted therapy for CML.
- While they can control symptoms, they do not target the underlying molecular defect in CML as effectively as TKIs.
*Monoclonal anti-HER-2 antibody*
- **Monoclonal anti-HER-2 antibodies** (e.g., trastuzumab) are used to treat **HER-2 positive breast cancer** and some gastric cancers.
- They are not relevant to the treatment of CML, which is characterized by the **BCR-ABL fusion gene**.
*Topoisomerase II inhibitor*
- **Topoisomerase II inhibitors** (e.g., etoposide, doxorubicin) prevent DNA unwinding and replication, leading to cell death, and are used in various hematologic malignancies and solid tumors.
- These drugs are broad-spectrum chemotherapeutic agents not specifically targeted to the **BCR-ABL fusion protein** in CML and are not first-line therapy for this condition.
*Monoclonal anti-CD20 antibody*
- **Monoclonal anti-CD20 antibodies** (e.g., rituximab) target the CD20 protein on B lymphocytes and are primarily used to treat **B-cell non-Hodgkin lymphoma** and some autoimmune diseases.
- They have no role in the direct treatment of CML, which is a myeloid malignancy.
Question 165: An 18-month-old boy is brought to the physician because of walking difficulties. His mother says that he cannot walk unless he is supported. She has also noted orange, sandy residues in his diapers. Over the past year, she has frequently caught him pulling his toenails and chewing the tips of his fingers. Examination shows scarring of his fingertips. Muscle tone is decreased in the upper and lower extremities. He cannot pick up and hold small objects between the tips of the index finger and the thumb. The most appropriate pharmacotherapy for this patient's condition inhibits which of the following conversions?
A. Hypoxanthine to inosine monophosphate
B. Adenosine to inosine
C. Ornithine to citrulline
D. Orotate to uridine monophosphate
E. Xanthine to urate (Correct Answer)
Explanation: ***Xanthine to urate***
- The patient's symptoms (developmental delay, self-mutilation, hypotonia, orange sandy residues in diapers) are classic for **Lesch-Nyhan syndrome**, which is caused by a deficiency of **hypoxanthine-guanine phosphoribosyltransferase (HGPRT)**.
- This deficiency leads to increased production of uric acid; the most appropriate pharmacotherapy is **allopurinol**, which inhibits **xanthine oxidase**, thereby blocking the conversion of xanthine to urate and reducing uric acid levels.
*Hypoxanthine to inosine monophosphate*
- This conversion is part of the **salvage pathway** catalyzed by **HGPRT**, which is deficient in Lesch-Nyhan syndrome.
- Inhibiting this step would worsen the underlying deficiency and is not a therapeutic strategy for this condition.
*Adenosine to inosine*
- This conversion is catalyzed by **adenosine deaminase (ADA)**. A deficiency in ADA leads to **severe combined immunodeficiency (SCID)**, not Lesch-Nyhan syndrome.
- While ADA deficiency involves purine metabolism, its clinical presentation and treatment are distinct.
*Ornithine to citrulline*
- This step is part of the **urea cycle**, catalyzed by **ornithine transcarbamylase (OTC)**.
- Deficiency in OTC results in **hyperammonemia** and neurological symptoms, but not the specific features of Lesch-Nyhan syndrome like self-mutilation or hyperuricemia.
*Orotate to uridine monophosphate*
- This conversion is involved in **pyrimidine synthesis**, catalyzed by **uridine monophosphate synthase**.
- A defect in this pathway leads to **orotic aciduria**, characterized by megaloblastic anemia and growth retardation, which is different from the presentation of Lesch-Nyhan syndrome.
Question 166: A 60-year-old man is rushed to the emergency room after he was found unconscious in bed that afternoon. The patient’s wife says he has been confused and irritable for the past several days. She says he has a history of chronic daily alcohol abuse and has been hospitalized multiple times with similar symptoms His temperature is 37°C (98.6°F), the blood pressure is 110/80 mm Hg, the pulse is 90/min, and the respiratory rate is 14/min. On physical examination, the patient is minimally responsive to painful stimuli. His abdomen is distended with positive shifting dullness. Laboratory results are as follows:
Complete blood count
Hematocrit 35%
Platelets 100,000/mm3
White blood cells 5000/mm3
Liver function studies
Serum Albumin 2 g/dL
Alkaline phosphatase (ALP) 200 IU/L
Aspartate aminotransferase (AST) 106 IU/L
Alanine aminotransferase (ALT) 56 IU/L
The patient is admitted to the hospital and started on the appropriate treatment to improve his mental status. Which of the following best describes the mechanism of action of the drug that is most likely used to treat this patient’s symptoms?
A. Prevents the conversion of ammonia into ammonium
B. Increases ammonia production and absorption
C. Increases pH in the gastrointestinal lumen
D. Decreases pH in the gastrointestinal lumen (Correct Answer)
E. Decreases the colonic concentration of bacteria
Explanation: ***Decreases pH in the gastrointestinal lumen***
- The patient's presentation with altered mental status, chronic alcohol abuse, distended abdomen with shifting dullness (*ascites*), and abnormal liver function tests (low *albumin*, elevated *AST/ALT*) is highly suggestive of **hepatic encephalopathy**.
- **Lactulose** is the mainstay treatment for hepatic encephalopathy, and its mechanism involves lowering the colonic pH, which converts ammonia (NH3) into poorly absorbed ammonium (NH4+), thereby reducing systemic ammonia levels.
*Prevents the conversion of ammonia into ammonium*
- This statement is incorrect; the goal of treatment for hepatic encephalopathy is to **promote** the conversion of ammonia to ammonium to prevent its absorption.
- Ammonia (NH3) is lipophilic and readily crosses the blood-brain barrier, while ammonium (NH4+) is hydrophilic and poorly absorbed from the gut.
*Increases ammonia production and absorption*
- This is incorrect and would exacerbate hepatic encephalopathy by increasing the toxic ammonia load.
- The primary aim of treatment is to **reduce** ammonia production and enhance its excretion or conversion into a non-absorbable form.
*Increases pH in the gastrointestinal lumen*
- Elevating the pH in the colon would favor the production of **ammonia (NH3)** from ammonium (NH4+), leading to increased systemic ammonia absorption and worsening hepatic encephalopathy.
- Therefore, this mechanism would be detrimental to a patient with hepatic encephalopathy.
*Decreases the colonic concentration of bacteria*
- While **rifaximin** (a non-absorbable antibiotic) does decrease ammonia-producing bacteria in the gut and is used in conjunction with lactulose, this option describes the mechanism of an antibiotic, not the primary action of lactulose.
- Lactulose itself does not primarily decrease the overall concentration of gut bacteria, but rather modifies the *metabolic activity* of the existing bacteria.
Question 167: A 25-year-old man presents with abdominal pain and bloody diarrhea. His symptoms have been recurrent for the past few months, and, currently, he says he is having on average four bowel movements daily, often bloody. He describes the pain as cramping and localized to the left side of his abdomen. He also says that he has lost around 4.5 kg (10 lb) over the past 3 months. There is no other significant past medical history and the patient is not on current medications. His temperature is 37.7° C (100.0° F), pulse rate is 100/min, respiratory rate is 18/min, and blood pressure is 123/85 mm Hg. On physical examination, there is mild tenderness to palpation in the lower left quadrant of the abdomen with no rebound or guarding. Laboratory studies show anemia and thrombocytosis. Colonoscopy is performed, which confirms the diagnosis of ulcerative colitis (UC). What is the mechanism of action of the recommended first-line medication for the treatment of this patient’s condition?
A. Suppression of cellular and humoral immunity
B. TNF-⍺ antagonism
C. Inhibition of enzyme phospholipase A2
D. Cross-linking of bacterial DNA
E. Inhibition of leukotriene synthesis and lipoxygenase (Correct Answer)
Explanation: ***Inhibition of leukotriene synthesis and lipoxygenase***
- The first-line medications for mild to moderate ulcerative colitis (UC) are **aminosalicylates** like **mesalamine** (5-ASA).
- Mesalamine is thought to exert its anti-inflammatory effects by inhibiting **leukotriene synthesis** and the **lipoxygenase pathway**, thereby reducing inflammation in the colon.
*Suppression of cellular and humoral immunity*
- This mechanism of action describes **immunosuppressants** such as azathioprine or methotrexate, which are typically used for more severe or refractory cases of UC, not as first-line therapy.
- These drugs broadly suppress the immune system, leading to a higher risk of infections and other side effects.
*TNF-⍺ antagonism*
- This is the mechanism of action of **biologic agents** like infliximab or adalimumab, which are reserved for moderate to severe UC that has not responded to conventional therapy.
- **TNF-α inhibitors** block the inflammatory cytokine TNF-α, reducing inflammation but are not the initial treatment choice.
*Inhibition of enzyme phospholipase A2*
- This mechanism describes **corticosteroids** such as prednisone or budesonide, which are used to induce remission in moderate to severe UC flares, but not as first-line maintenance therapy due to significant side effects.
- Corticosteroids inhibit **phospholipase A2**, thereby blocking the entire arachidonic acid cascade and the production of all inflammatory mediators.
*Cross-linking of bacterial DNA*
- This mechanism describes **antibiotics** like metronidazole or ciprofloxacin, which work by cross-linking DNA in bacteria.
- While antibiotics may be used in specific UC scenarios (such as pouchitis or suspected superimposed infection), UC itself is an idiopathic inflammatory disease, not a bacterial infection, and antibiotics are not first-line treatment for the underlying condition.
Question 168: A 46-year-old male presents to his dermatologist for routine follow-up of his psoriasis. He was last seen in the office six months prior, at which time he started undergoing ultraviolet light therapy. He reports that he initially noticed an improvement in his symptoms but the effects were transient. He has also started noticing pain and stiffness in his fingers. His past medical history is notable for obesity and diabetes mellitus. He takes metformin. His temperature is 99°F (37.2°C), blood pressure is 130/80 mmHg, pulse is 80/min, and respirations are 16/min. Multiple plaques with scaling are noted on the extensor surfaces of the upper and lower extremities. The patient’s physician suggests stopping the ultraviolet light therapy and starting an injectable medication that acts as a decoy receptor for a pro-inflammatory cytokine. Which of the following is an adverse effect associated with the use of this medication?
A. Cushing’s syndrome
B. Retinopathy
C. Myelosuppression
D. Reactivation of latent tuberculosis (Correct Answer)
E. Nephrotoxicity
Explanation: ***Reactivation of latent tuberculosis***
- The patient's symptoms (psoriasis with associated arthralgias) suggest **psoriatic arthritis**. The physician's recommendation for an injectable medication acting as a decoy receptor for a **pro-inflammatory cytokine** refers to a **TNF-α inhibitor** (e.g., etanercept, infliximab, adalimumab).
- TNF-α inhibitors suppress the immune system, making patients susceptible to **opportunistic infections**, including the **reactivation of latent tuberculosis** (TB). Screening for latent TB is crucial before initiating these medications.
*Cushing’s syndrome*
- **Cushing's syndrome** is caused by prolonged exposure to high levels of **glucocorticoids**, either endogenous (e.g., adrenal tumors) or exogenous (e.g., long-term steroid use).
- TNF-α inhibitors do not directly cause Cushing's syndrome; they are **biologic agents** that target specific inflammatory pathways.
*Retinopathy*
- **Retinopathy** is a condition affecting the retina, often associated with systemic diseases like **diabetes** or medications such as **hydroxychloroquine**.
- TNF-α inhibitors are not typically associated with retinopathy as a direct side effect.
*Myelosuppression*
- **Myelosuppression** (bone marrow suppression) is a common adverse effect of **chemotherapeutic agents** and some immunosuppressants (e.g., methotrexate, azathioprine).
- While TNF-α inhibitors can rarely cause hematologic abnormalities, significant myelosuppression is not a characteristic or common adverse effect compared to traditional cytotoxic drugs.
*Nephrotoxicity*
- **Nephrotoxicity** refers to kidney damage caused by drugs, such as **NSAIDs**, aminoglycosides, or certain chemotherapeutic agents.
- TNF-α inhibitors are not primarily associated with nephrotoxicity as a significant adverse effect.
Question 169: An 8-year-old boy is brought to the emergency department by his parents because of sudden onset of abdominal pain beginning an hour ago. The parents report that their son has also had an episode of dark urine earlier that morning. Three days ago, he was diagnosed with a urinary tract infection and was treated with trimethoprim-sulfamethoxazole. He emigrated from Liberia to the US with his family 3 years ago. There is no personal history of serious illness. His immunizations are up-to-date. Vital signs are within normal limits. Examination shows diffuse abdominal tenderness and scleral icterus. The spleen is palpated 1–2 cm below the left costal margin. Laboratory studies show:
Hemoglobin 10 g/dL
Mean corpuscular volume 90 μm3
Reticulocyte count 3%
Serum
Bilirubin
Total 3 mg/dL
Direct 0.5 mg/dL
Haptoglobin 20 mg/dL (N=41–165 mg/dL)
Lactate dehydrogenase 160 U/L
Urine
Blood 3+
Protein 1+
RBC 2–3/hpf
WBC 2–3/hpf
Which of the following is the most likely underlying cause of this patient's symptoms?
A. Production of hemoglobin S
B. Deficient glucose-6-phosphate dehydrogenase (Correct Answer)
C. Lead poisoning
D. Cold agglutinins
E. Defective RBC membrane proteins
Explanation: ***Deficient glucose-6-phosphate dehydrogenase***
- The patient's presentation with **hemolytic anemia** (low hemoglobin, elevated reticulocytes, low haptoglobin, elevated LDH, elevated indirect bilirubin) following **trimethoprim-sulfamethoxazole** administration, along with dark urine (hemoglobinuria), is highly suggestive of G6PD deficiency.
- G6PD deficiency is common in individuals of African descent (patient emigrated from Liberia) and certain medications like sulfa drugs can trigger **oxidative stress** leading to hemolysis in affected individuals.
*Production of hemoglobin S*
- While **sickle cell anemia** (due to hemoglobin S) can cause hemolytic anemia and abdominal pain (**vaso-occlusive crisis**), the sudden onset linked to a specific medication and the absence of a prior history of serious illness make G6PD deficiency more likely.
- Sickle cell disease typically presents with recurrent painful crises, dactylitis in infancy, and chronic hemolytic anemia, which are not described here.
*Lead poisoning*
- **Lead poisoning** can cause abdominal pain and anemia, but it typically presents with a **microcytic hypochromic anemia** and **basophilic stippling** on peripheral smear.
- It does not directly cause an acute hemolytic crisis triggered by trimethoprim-sulfamethoxazole.
*Cold agglutinins*
- **Cold agglutinin disease** involves hemolytic anemia triggered by cold exposure, and the antibodies react optimally at cold temperatures.
- The patient's symptoms are acute and triggered by a medication known to induce oxidative stress, which is not characteristic of cold agglutinin disease.
*Defective RBC membrane proteins*
- **Hereditary spherocytosis** (a defect in RBC membrane proteins like spectrin or ankyrin) causes chronic hemolytic anemia and splenomegaly.
- While it can manifest with jaundice, it typically does not cause an acute, drug-induced hemolytic crisis with hemoglobinuria as seen here.
Question 170: A 45-year-old male presents to his primary care doctor complaining of abdominal pain. He reports a three-month history of intermittent burning pain localized to the epigastrium that worsens 2-3 hours after a meal. He attributes this pain to increased stress at his job. He is otherwise healthy and takes no medications. He does not smoke or drink alcohol. His temperature is 98.8°F (37.1°C), blood pressure is 130/85 mmHg, pulse is 90/min, and respirations are 18/min. Physical examination reveals mild epigastric tenderness to palpation. A urease breath test is positive. Which of the following treatments is most appropriate first-line therapy for this patient?
A. Octreotide
B. Sulfasalazine
C. Amoxicillin, clarithromycin, and omeprazole (Correct Answer)
D. Tetracycline, omeprazole, bismuth, and metronidazole
E. Pantoprazole
Explanation: ***Amoxicillin, clarithromycin, and omeprazole***
- The patient's symptoms (epigastric burning pain worsening 2-3 hours after meals) and a **positive urease breath test** strongly suggest a *Helicobacter pylori* infection causing a peptic ulcer or gastritis.
- The standard first-line eradication therapy for *H. pylori* is **triple therapy**, which typically includes a **proton pump inhibitor (PPI)** like omeprazole and two antibiotics, usually **amoxicillin** and **clarithromycin**.
*Octreotide*
- **Octreotide** is a somatostatin analog used primarily for conditions causing excessive hormone secretion, such as **variceal bleeding**, neuroendocrine tumors (e.g., carcinoid syndrome, VIPomas), and acromegaly.
- It is not indicated for the treatment of *H. pylori* infection or peptic ulcer disease in this context.
*Sulfasalazine*
- **Sulfasalazine** is an anti-inflammatory drug primarily used in the management of **inflammatory bowel disease (IBD)**, such as ulcerative colitis and Crohn's disease, and some forms of rheumatoid arthritis.
- It has no role in the eradication of *H. pylori* or the treatment of peptic ulcer disease.
*Tetracycline, omeprazole, bismuth, and metronidazole*
- This combination, known as **quadruple therapy**, is primarily used as **second-line treatment** for *H. pylori* eradication, especially in cases of **treatment failure** with triple therapy or in areas with **high clarithromycin resistance**.
- While effective, it's not the initial first-line approach when there's no known resistance or prior treatment failure.
*Pantoprazole*
- **Pantoprazole** is a proton pump inhibitor (PPI) that reduces gastric acid secretion and would alleviate the patient's symptoms.
- However, using a PPI alone would only suppress symptoms and **would not eradicate the underlying *H. pylori* infection**, allowing the infection and potential ulceration to persist.